Brian Bergmark, Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Boston, USA, considers the substantial TG reduction with olezarsen seen in the ESSENCE-TIMI 73b trial of olezarsen, alongside the lack of effect on non-calcified plaque volume.
Please login or create a FREE account to view this content
Educational Supporters of the 12th Closed Scientific Expert Meeting of the Editorial Board
Principal supporters:
Guest supporters:
